Gene · 1237
Papers2,300
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,300
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer. | Cancer Res Commun | 2024 | 38181044 | PubTator, text mining | PubMed |
| CC chemokine receptors are prognostic indicators of gastric cancer and are associated with immune infiltration. | BMC Med Genomics | 2024 | 38169378 | PubTator, text mining | PubMed |
| NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. | J Exp Clin Cancer Res | 2024 | 38167224 | PubTator, text mining | PubMed |
| Characterization of Cell Type Abundance and Gene Expression Timeline from Burned Skin Bulk Transcriptomics by Deconvolution. | J Burn Care Res | 2024 | 37956340 | PubTator, text mining | PubMed |
| Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells. | J Mol Cell Biol | 2024 | 37935468 | PubTator, text mining | PubMed |
| Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients. | Br J Ophthalmol | 2024 | 36918273 | PubTator, text mining | PubMed |
| Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity. | Front Immunol | 2023 | 38283365 | PubTator, text mining | PubMed |
| New era of cancer immunology driven by big data. | Med Rev (2021) | 2023 | 38282800 | PubTator, text mining | PubMed |
| Macrophage plasticity and function in cancer and pregnancy. | Front Immunol | 2023 | 38274812 | PubTator, text mining | PubMed |
| Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma. | Front Immunol | 2023 | 38274805 | PubTator, text mining | PubMed |
| Limitations and potential of immunotherapy in ovarian cancer. | Front Immunol | 2023 | 38264664 | PubTator, text mining | PubMed |
| Heterogeneity and subtypes of CD4+ regulatory T cells: implications for tumor therapy. | Front Immunol | 2023 | 38250084 | PubTator, text mining | PubMed |
| Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential. | Cancers (Basel) | 2023 | 38201551 | PubTator, text mining | PubMed |
| Multilevel Heterogeneity of Colorectal Cancer Liver Metastasis. | Cancers (Basel) | 2023 | 38201487 | PubTator, text mining | PubMed |
| HTRA1 expression is associated with immune-cell infiltration and survival in breast cancer. | Transl Cancer Res | 2023 | 38197075 | PubTator, text mining | PubMed |
| Multiomics insights on the onset, progression, and metastatic evolution of breast cancer. | Front Oncol | 2023 | 38169859 | PubTator, text mining | PubMed |
| Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy. | Cancers (Basel) | 2023 | 38136421 | PubTator, text mining | PubMed |
| BET Protein Inhibitor JQ1 Ameliorates Experimental Peritoneal Damage by Inhibition of Inflammation and Oxidative Stress. | Antioxidants (Basel) | 2023 | 38136175 | PubTator, text mining | PubMed |
| DJ-1: A Potential Biomarker Related to Prognosis, Chemoresistance, and Expression of Microenvironmental Chemokine in HR-Positive Breast Cancer. | J Immunol Res | 2023 | 38125697 | PubTator, text mining | PubMed |
| Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease. | Stem Cell Res Ther | 2023 | 38111001 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1237/papers?page=8